The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Dr Lisa Fuller joins Ethics Talk to discuss her article: “How Should Organizations and Clinicians Help Marginalized Patients Manage Loneliness as a Harm of Climate Change?”
High reliability organizations operate in complex, high-hazard domains for extended periods without serious accidents, catastrophic failures, or ecological health threats.
AMA J Ethics. 2024;26(2):E171-178. doi:
10.1001/amajethics.2024.171.
Dr Jamaji C. Nwanaji-Enwerem joins Ethics Talk to discuss his collection of images: Intentionally Retained, Intentionally Fragmented, Accidentally Retained, and Accidentally Fragmented.
Dr Joost van Herten joins Ethics Talk to discuss how comparing different conceptions of health can help us interrogate just exactly what a One Health approach to health offers and what it doesn't.